A novel antiangiogenesis treatment for patients with cancer may be effective in the form of nose drops.
The drug, a thymic peptide known as IM862, is now well into phase 3 clinical trials. But data from phase 2 trials presented last month at the American Society of Clinical Oncology meeting in Atlanta showed that IM862 can reduce tumors and eliminate lesions. The study, by researchers at the University of Southern California School of Medicine, found that of 35 patients with Kaposi sarcoma (KS) who took the drug as a nose drop, lesions completely resolved in four patients and nine had partial reduction in tumor size within 6 weeks of starting treatment. In 17 patients, no disease progression occurred for at least 6 months. The most frequent adverse effect was mild headache.
Voelker R. Cancer Drug in Nasal Drops. JAMA. 1999;281(24):2277. doi:10.1001/jama.281.24.2277